Education
About Us
Working with TipRanks
Follow Us
Embecta Corporation (EMBC)
NASDAQ:EMBC
EMBC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.20 - $21.48
Previous CloseN/A
Volume119.84K
Average Volume (3M)507.52K
Market Cap
$837.51M
Enterprise Value$1.85B
Total Cash (Recent Filing)$230.60M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)10.0
Beta1.05
Next Earnings
Dec 23, 2025EPS Estimate
0.46Last Dividend Ex-Date
Aug 29, 2025Dividend Yield4.19%
Share Statistics
EPS (TTM)1.12
Shares Outstanding58,485,120
10 Day Avg. Volume440,228
30 Day Avg. Volume507,518
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.21
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda7.18
Forecast
1Y Price Target
$16.67Price Target Upside16.41% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Debt ReductionEMBC expects to reduce its debt by $150M this fiscal year while simultaneously driving $7M-$8M in pre-tax cost savings in the second half of the fiscal year.
Financial PerformanceEmbecta reported F3Q revenue of $295.5M, $17M above consensus, with pricing and volume benefits contributing equally to the outperformance.
Pipeline InitiativesEMBC is in active talks with more than 30 pharmaceutical companies to potentially copackage their pen needle products with generic GLP-1s and has signed a handful of agreements.
Bears Say
Geopolitical ConcernsEMBC expressed near-term concern about the Chinese market, where distributors have reported customers buying more local Chinese brands as a result of tariffs and recent geopolitical tensions.
Revenue ProjectionsThe full-year guide implies a ~$30M sequential decrease in revenue for F4Q at the midpoint, reflecting the reversal of the benefits from timing of distributor orders and stocking in F3Q, in addition to rebate reserve adjustments.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $9.20 and its highest was $21.48 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $837.51M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is Dec 23, 2025 which is in 78 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on Aug 08, 2025. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.775 by $0.345.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Undervalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 4.19%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.46.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 58,485,120 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $1.12 in its last earnings report, beating expectations of $0.775. Following the earnings report the stock price went up 18.537%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
Embecta Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$16.67 (16.41% Upside)
$16.67 (16.41% Upside)
Blogger Sentiment
Bullish
EMBC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 424.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.44%
12-Months-Change
Fundamentals
Return on Equity
-10.61%
Trailing 12-Months
Asset Growth
-8.69%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Embecta's earnings call highlighted strong revenue performance and successful strategic initiatives such as ERP implementation and debt reduction. However, challenges remain with declining China revenue and expected reductions in margins and revenue in the fourth quarter. While the call contained significant positive developments, these were tempered by notable challenges.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$16.67
▲(16.41% Upside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
2.22% Insiders
30.46% Mutual Funds
30.81% Other Institutional Investors
11.87% Public Companies and
Individual Investors